Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects ea...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00884/full |
id |
doaj-e6b42e00ab1d407c9c50c66883fb0686 |
---|---|
record_format |
Article |
spelling |
doaj-e6b42e00ab1d407c9c50c66883fb06862020-11-24T20:53:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-08-011010.3389/fphar.2019.00884460082Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing PlatformsBrian D. Guth0Brian D. Guth1Michael Engwall2Sandy Eldridge3C. Michael Foley4Liang Guo5Gary Gintant6John Koerner7Stanley T. Parish8Jennifer B. Pierson9Alexandre J. S. Ribeiro10Tanja Zabka11Khuram W. Chaudhary12Yasunari Kanda13Brian Berridge14Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, GermanyPreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South AfricaSafety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United StatesDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesDepartment of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United StatesLaboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United StatesDepartment of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United StatesCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United StatesHealth and Environmental Sciences Institute, Washington, DC, United StatesHealth and Environmental Sciences Institute, Washington, DC, United StatesDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States0Department of Safety Assessment, Genentech, South San Francisco, CA, United States1Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States2Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan3National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, United StatesDrug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, in vitro test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given drug affects cardiac contractility. Finally, there could be in vitro testing platforms that could ultimately contribute to the regulatory safety package of a new drug. The characteristics needed for a successful cell or tissue-based testing platform for cardiac contractility will be dictated by its intended use. In this article, general considerations are presented with the intent of guiding the development of new testing platforms that will find utility in drug research and development. In the following article (part 2), specific aspects of using human-induced stem cell-derived cardiomyocytes for this purpose are addressed.https://www.frontiersin.org/article/10.3389/fphar.2019.00884/fullcontractilityinotropic statecardiomyocytestem cellsmyocardium |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brian D. Guth Brian D. Guth Michael Engwall Sandy Eldridge C. Michael Foley Liang Guo Gary Gintant John Koerner Stanley T. Parish Jennifer B. Pierson Alexandre J. S. Ribeiro Tanja Zabka Khuram W. Chaudhary Yasunari Kanda Brian Berridge |
spellingShingle |
Brian D. Guth Brian D. Guth Michael Engwall Sandy Eldridge C. Michael Foley Liang Guo Gary Gintant John Koerner Stanley T. Parish Jennifer B. Pierson Alexandre J. S. Ribeiro Tanja Zabka Khuram W. Chaudhary Yasunari Kanda Brian Berridge Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms Frontiers in Pharmacology contractility inotropic state cardiomyocyte stem cells myocardium |
author_facet |
Brian D. Guth Brian D. Guth Michael Engwall Sandy Eldridge C. Michael Foley Liang Guo Gary Gintant John Koerner Stanley T. Parish Jennifer B. Pierson Alexandre J. S. Ribeiro Tanja Zabka Khuram W. Chaudhary Yasunari Kanda Brian Berridge |
author_sort |
Brian D. Guth |
title |
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
title_short |
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
title_full |
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
title_fullStr |
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
title_full_unstemmed |
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms |
title_sort |
considerations for an in vitro, cell-based testing platform for detection of adverse drug-induced inotropic effects in early drug development. part 1: general considerations for development of novel testing platforms |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-08-01 |
description |
Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, in vitro test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given drug affects cardiac contractility. Finally, there could be in vitro testing platforms that could ultimately contribute to the regulatory safety package of a new drug. The characteristics needed for a successful cell or tissue-based testing platform for cardiac contractility will be dictated by its intended use. In this article, general considerations are presented with the intent of guiding the development of new testing platforms that will find utility in drug research and development. In the following article (part 2), specific aspects of using human-induced stem cell-derived cardiomyocytes for this purpose are addressed. |
topic |
contractility inotropic state cardiomyocyte stem cells myocardium |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.00884/full |
work_keys_str_mv |
AT briandguth considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT briandguth considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT michaelengwall considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT sandyeldridge considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT cmichaelfoley considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT liangguo considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT garygintant considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT johnkoerner considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT stanleytparish considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT jenniferbpierson considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT alexandrejsribeiro considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT tanjazabka considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT khuramwchaudhary considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT yasunarikanda considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms AT brianberridge considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms |
_version_ |
1716797761477672960 |